Clinical Trial Update: AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

AbbVie announced completion of the Phase I/II trial of AGN-151597 (formerly RST-001) for retinitis pigmentosa, with results posted in June 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• AGN-151597 (RST-001)

Snippet

Sponsor: AbbVie | Conditions: Advanced Retinitis Pigmentosa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-23